Stockscreener 앱 받기
28.00
3.61%
-1.05
시간 외 거래:
27.91
-0.09
-0.32%
Faeth Therapeutics Inc 주식(FTH)의 최신 뉴스
Faeth Therapeutics Adds Cancer Expert to Board - TipRanks
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to S&P Biotechnology Select Industry Index - marketscreener.com
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion - Seeking Alpha
Faeth Therapeutics appoints Karen Vousden to board By Investing.com - Investing.com Nigeria
Faeth Therapeutics (FTH) Adds Renowned Cancer Biologist Dr. Kare - gurufocus.com
Faeth Therapeutics appoints Karen Vousden to board - Investing.com
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors - Yahoo Finance
Faeth stock gets new Buy at Guggenheim (FTH:NASDAQ) - Seeking Alpha
Faeth Therapeutics at Morgan Stanley conference: oral cancer strategy By Investing.com - Investing.com Nigeria
FTH Initiated Coverage by Guggenheim -- Price Target Announced a - GuruFocus
Faeth Therapeutics Director Karen H. Vousden Granted 25,000 Stock Options - Kalkine Media
Faeth Therapeutics (FTH) awards 25,000 stock options to director - stocktitan.net
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FTH Initiates Coverage On by Lucid Capital Markets -- Price Targ - GuruFocus
Faeth Therapeutics at Cantor Fitzgerald conference: oral PI3K push By Investing.com - Investing.com Canada
A booming business on Wall Street would love more biotechs to quietly die - BioPharma Dive
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
FTH Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating - Yahoo Finance
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - BioSpace
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
Faeth Therapeutics stock hits 52-week high at 40.89 USD By Investing.com - Investing.com Australia
Faeth Therapeutics stock hits 52-week high at 40.89 USD - investing.com
Bullish Faeth Therapeutics Insiders Rewarded As Their Investment Rises To US$1.94m - simplywall.st
Insiders of Faeth Therapeutics Getting Good Value On Their US$1.19m Investment - Moomoo
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Eastern Progress
Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
Faeth Therapeutics (FTH) Grants Stock Options to New Hires Amid Unprofitable Growth Phase - GuruFocus
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Capital expenditures of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know - Yahoo Finance
FAETH THERAPEUTICS, INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $56 - Bitget
Needham initiates Faeth Therapeutics stock with buy rating on cancer drug potential - Investing.com Canada
FTH Initiates Coverage On by Needham -- Buy Rating with $56 Pric - GuruFocus
Needham Initiates Faeth Therapeutics at Buy With $56 Price Target - Yahoo Finance
Khosla Ventures Seed Associates D, Llc Net Worth (2026) - GuruFocus
Why is Faeth Therapeutics stock surging today? By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace
FDA grants fast track status to Faeth’s endometrial cancer drug - Investing.com
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus
FDA grants fast track status to Faeth’s endometrial cancer drug By Investing.com - Investing.com Canada
Faeth Therapeutics Gets US FDA Fast Track Designation for Endometrial Cancer Drug Combination - Yahoo Finance
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth TherapeuticsFTHStock Price & News - fool.com
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - kalkine.ca
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments - TradingView
Faeth Therapeutics Adds Senior Leaders Ahead of PIKTOR Clinical Milestones - citybiz
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - BioSpace
Faeth Therapeutics names two senior vice presidents - Investing.com
3.06%
2.55%
자본화:
|
볼륨(24시간):